ARVN
Price
$6.90
Change
+$0.06 (+0.88%)
Updated
Oct 14, 11:02 AM (EDT)
Capitalization
491.05M
27 days until earnings call
Intraday BUY SELL Signals
XNCR
Price
$23.76
Change
+$0.24 (+1.02%)
Updated
Oct 14, 11:23 AM (EDT)
Capitalization
1.9B
26 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARVN vs XNCR

ARVN vs XNCR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARVN vs. XNCR commentary
Oct 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a Hold and XNCR is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARVN with price predictions
Oct 13, 2026

ARVN in downward trend: price dove below 50-day moving average on September 10, 2026

ARVN moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend. In 35 of 37 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARVN as a result. In 77 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for ARVN turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 37 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

The 10-day moving average for ARVN crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for ARVN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ARVN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +2.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARVN advanced for three days, in 204 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

ARVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. ARVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.874) is normal, around the industry mean (26.782). P/E Ratio (28.885) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1.733) is also within normal values, averaging (437.542).

The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for XNCR with price predictions
Oct 13, 2026

XNCR in +2.20% Uptrend, rising for three consecutive days on October 12, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where XNCR advanced for three days, in 189 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis
Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 52 cases where XNCR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.

The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XNCR as a result. In 60 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.

XNCR moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for XNCR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

XNCR broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for XNCR entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.782) is normal, around the industry mean (26.782). P/E Ratio (72.464) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (437.542).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ARVN vs XNCR: Fundamental Ratings
ARVN
XNCR
OUTLOOK RATING
1..100
5582
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8397
PRICE GROWTH RATING
1..100
7735
P/E GROWTH RATING
1..100
595
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARVN's Valuation (78) in the Biotechnology industry is in the same range as XNCR (88). This means that ARVN’s stock grew similarly to XNCR’s over the last 12 months.

ARVN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as XNCR (100). This means that ARVN’s stock grew similarly to XNCR’s over the last 12 months.

ARVN's SMR Rating (83) in the Biotechnology industry is in the same range as XNCR (97). This means that ARVN’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for ARVN (77). This means that XNCR’s stock grew somewhat faster than ARVN’s over the last 12 months.

XNCR's P/E Growth Rating (5) in the Biotechnology industry is somewhat better than the same rating for ARVN (59). This means that XNCR’s stock grew somewhat faster than ARVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARVNXNCR
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
79%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 3 days ago
74%
Declines
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 8 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
82%
COMPARISON
Comparison
Oct 14, 2026
Stock price -- (ARVN: $6.84 vs. XNCR: $23.52)
Brand notoriety: ARVN and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARVN: 115% vs. XNCR: 163%
Market capitalization -- ARVN: $491.05M vs. XNCR: $1.9B
ARVN [@Biotechnology] is valued at $491.05M. XNCR’s [@Biotechnology] market capitalization is $1.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARVN’s FA Score shows that 0 FA rating(s) are green while XNCR’s FA Score has 1 green FA rating(s).

  • ARVN’s FA Score: 0 green, 5 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, XNCR is a better buy in the long-term than ARVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARVN’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 1 bullish TA indicator(s).

  • ARVN’s TA Score: 4 bullish, 6 bearish.
  • XNCR’s TA Score: 1 bullish, 7 bearish.
According to our system of comparison, ARVN is a better buy in the short-term than XNCR.

Price Growth

ARVN (@Biotechnology) experienced а -6.43% price change this week, while XNCR (@Biotechnology) price change was -3.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.22%. For the same industry, the average monthly price growth was -17.98%, and the average quarterly price growth was -18.86%.

Reported Earning Dates

ARVN is expected to report earnings on Nov 10, 2026.

XNCR is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-7.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ARVN
Daily Signal:
Gain/Loss:
XNCR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WS39.201.21
+3.19%
Worthington Steel
SLNHP11.440.05
+0.44%
Soluna Holdings
EDU58.620.18
+0.31%
New Oriental Education and Technology Group
TTEC1.64-0.03
-1.80%
TTEC Holdings
ASPI2.28-0.16
-6.56%
ASP Isotopes

ARVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with BCYC. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then BCYC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
-8.19%
BCYC - ARVN
46%
Loosely correlated
-4.47%
AXON - ARVN
46%
Loosely correlated
-0.26%
VCYT - ARVN
46%
Loosely correlated
-2.07%
OLMA - ARVN
45%
Loosely correlated
-4.62%
XNCR - ARVN
45%
Loosely correlated
-6.07%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
-6.07%
VCYT - XNCR
52%
Loosely correlated
-2.07%
KURA - XNCR
50%
Loosely correlated
-5.44%
RCUS - XNCR
48%
Loosely correlated
-7.52%
VIR - XNCR
47%
Loosely correlated
-6.11%
CLDX - XNCR
45%
Loosely correlated
-4.01%
More